zoledronic acid


Mega Lifesciences


Zuellig Pharma
Concise Prescribing Info
Zoledronic acid
Treatment of moderate to severe hypercalcemia of malignancy (HCM). Osteolytic, osteoblastic & mixed bone metastases of solid tumors & osteolytic lesion of multiple myeloma in conjunction w/ standard antineoplastic therapy. Reduction of bone damage in patients w/ advanced bone malignancies.
Dosage/Direction for Use
Max: 4 mg as a single IV infusion dose over ≥15 min. Bone metastases & osteolytic lesions Infuse 4 mg every 3-4 wk over ≥15 min.
Hypersensitivity to bisphosphonates. Patients w/ bone metastasis & severe renal impairment, serum creatinine >3 mg/dL. Pregnancy.
Special Precautions
Hypercalcemia associated w/ hyperparathyroidism or w/ other nontumor-related conditions. Hydration & electrolyte monitoring prior to administration. Renal & hepatic impairment. Osteonecrosis of the jaw. Discontinue if severe bone, joint &/or muscle pain develop. Asthma. Lactation. Childn. Elderly.
Adverse Reactions
Nausea, constipation, fatigue, confusion, hallucination, anemia, leucopenia, thrombocytopenia, muscle pain, vomiting, weakness, anorexia, fever, dyspnea, eye irritation, hypocalcemia, headache, diarrhea, bone pain, hypophosphatemia.
Drug Interactions
Must not be mixed w/ Ca or other divalent cation-containing infusion soln eg, lactated Ringer's. Aminoglycosides, loop diuretics, nephrotoxic drugs, thalidomide.
MIMS Class
Agents Affecting Bone Metabolism
ATC Classification
M05BA08 - zoledronic acid ; Belongs to the class of bisphosphonates. Used in the treatment of bone diseases.
Zinvel infusion 4 mg/5 mL
5 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in